Detection of mutations in JAK2 exons 12-15 by Sanger sequencing.

about

JAK2 exon 12 mutation-positive myeloproliferative neoplasm associated with recurrent thromboembolism.Polycythemia vera treatment algorithm 2018.

P2860

Q42292600-ECD91A7C-30A4-4E3E-AB7F-4D90E1367C4E Q47565670-D3274725-E809-4932-B8B5-00EB1E097290

P2860

Detection of mutations in JAK2 exons 12-15 by Sanger sequencing.

Item

http://www.wikidata.org/entity/Q47908421

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Detection of mutations in JAK2 exons 12-15 by Sanger sequencing.

@en

Detection of mutations in JAK2 exons 12-15 by Sanger sequencing.

@nl

type

Item

label

Detection of mutations in JAK2 exons 12-15 by Sanger sequencing.

@en

Detection of mutations in JAK2 exons 12-15 by Sanger sequencing.

@nl

prefLabel

Detection of mutations in JAK2 exons 12-15 by Sanger sequencing.

@en

Detection of mutations in JAK2 exons 12-15 by Sanger sequencing.

@nl

P1476

Detection of mutations in JAK2 exons 12-15 by Sanger sequencing.

@en

P2093

H Abalkhail

http://www.w3.org/2001/XMLSchema#string

N Alghasham

http://www.w3.org/2001/XMLSchema#string

S Khalil

http://www.w3.org/2001/XMLSchema#string

Y Alnouri

http://www.w3.org/2001/XMLSchema#string

P2860

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Somatic mutations of calreticulin in myeloproliferative neoplasms.

The JAK2 exon 12 mutations: a comprehensive review.

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.

X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoies

On the molecular origins of the chronic myeloproliferative disorders: it all makes sense.

P304

34-41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IJLH.12425

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26361084

http://www.w3.org/2001/XMLSchema#string

Detection of mutations in JAK2 exons 12-15 by Sanger sequencing.

about

P2860

P2860

Detection of mutations in JAK2 exons 12-15 by Sanger sequencing.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698